Cardiovascular drugs inducing QT prolongation: Facts and evidence

Current Drug Safety

Volumn 5, Issue 1, 2010, Pages 65-72

  Taira, Carlos A ^a   Opezzo, Javier A W ^a   Mayer, Marcos A ^a   Höcht, Christian ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Amiodarone; Antiarrhythmic drugs; Drug induced torsades de pointes; HERG channel; QT interval; Sotalol

Indexed keywords

ADRENALIN; ALMOKALANT; AMBASILIDE; AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARDIOVASCULAR AGENT; DIGOXIN; DISOPYRAMIDE; DOBUTAMINE; DOFETILIDE; DOPAMINE; FLECAINIDE; IBUTILIDE; INDAPAMIDE; ISRADIPINE; MIBEFRADIL; MOEXIPRIL; NICARDIPINE; POTASSIUM CHANNEL HERG; PROCAINAMIDE; QUINIDINE; SEMATILIDE; SOTALOL; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VERAPAMIL;

BRADYCARDIA; BRUGADA SYNDROME; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENTIATION; GENDER; GENETIC PREDISPOSITION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DISEASE; HEART MUSCLE FIBROSIS; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOKALEMIA; IDIOPATHIC VENTRICULAR FIBRILLATION; KIDNEY FAILURE; LIVER FAILURE; LONG QT SYNDROME; LOW DRUG DOSE; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; QT DISPERSION; QT PROLONGATION; REVIEW; RR INTERVAL; SHORT QT SYNDROME; SIDE EFFECT; SINUS BRADYCARDIA; SUICIDE ATTEMPT; SYNCOPE; T WAVE; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT;

ANTI-ARRHYTHMIA AGENTS; CARDIOVASCULAR AGENTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LONG QT SYNDROME; MALE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TORSADES DE POINTES;

EID: 77950797376     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488610789869229     Document Type: Review

References (105)

1. Gorda RM, Khan IA, Wilbur SL, Vasavada BC, Sacchi TJ. Torsade de pointes: the clinical considerations. Int J Cardiol 2004; 96:1-6.
2. Shah RR. Drug-induced prolongation of the QT interval: why regulatory concern? Fundam Clin Pharmacol 2002; 16:119-124
3. Darpö B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J Suppl 2001; 3 (suppl K): K70-K80.
4. Al-Khatib SM, Allen LaPionte N, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA 2003; 289: 2120-2127
5. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350:1013-1022
6. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes. Drug Safety 2002; 25:263-286
7. Tamargo J, Caballero R, Gómez R, Valenzuela C, Delpón E. Pharmacology of cardiac potassium channels. Cardiovasc Res 2004; 62: 9-33.
8. Ravens U, Cerbai E. Role of potassium currents in cardiac arrhythmias. Europace 2008; 10: 1133-1137
9. Van Opstal JM, Schoenmakers M, Verduyn SC, et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 2001; 104: 2722-2727
10. Cubeddu LX. Qt prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther 2003; 10: 452-457
11. Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 2003; 24: 619-625
12. Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 2003; 45: 415-427
13. De Ponti F, Poluzzi E, Vaccheri A, et al. Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries. Br J Clin Pharmacol 2002; 54: 171-177
14. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol 2003; 91 (suppl): 39D-44D.
15. Zarȩba W. Drug induced QT prolongation. Cardiol J 2007; 14: 523-533
16. Vincent GM. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death. Annu Rev Med 1998; 49: 262-274
17. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long QT syndrome: clinical impact. Circulation 1999; 99: 529-533
18. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999; 354: 625-633
19. Boulet IR, Raes AL, Ottschytsch N, Snyders DJ, Roden DM. Functional effects of a KCNQ1 mutation associated with the long QT syndrome. Cardiovasc Res 2006; 70: 466-474
20. Schulze-Bahr E, Havercamp W, Eckardt L, Kirchhof L, Wedekind H, Breihardt G. Genetic aspects in acquired long QT syndrome-a piece in the puzzle. Eur Heart J Suppl 2001; 3 (suppl K): K48-K52.
21. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC y col. Allelic variants in long-QT disease genes in patients with drugassociated torsade de pointes. Circulation 2002; 105: 1943-1948
22. Bauman JL. The role of pharmacokinetics, drug interactions and pharmacogenetics in the acquired long QT syndrome. Eur Heart J Suppl 2001; 3 (suppl K): K93-K100.
23. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-355
24. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 2003; 55: 425-461
25. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549
26. Mehler PS. Diagnosis and care of patients with anorexia nervosa in primary care settings. Ann Intern Med 2001; 134: 1048-1059
27. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol 1983; 2: 806-817
28. Malik M, Farbom P, Batchhvarov V, Hnatkova K, Camm AJ. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 2002; 87: 220-228
29. Yang T, Roden DM. Extracellular potassium modulation of drug block of Ikr: implications for torsade de pointes and reverse usedependence. Circulation 1996; 93: 407-411
30. Gums JG. Magnesium in cardiovascular and other disorders. Am J Health-Syst Pharm 2004; 61: 1569-1576
31. Rieffel JA. Impact of structural heart disease on the selection of class III antiarrhythmics for the prevention of atrial fibrillation and flutter. Am Heart J 1998; 135: 551-556
32. Han WE, Chartier D, Li D, Nattel S. Ionic remodeling in cardiac Purkinje cells by congestive heart failure. Circulation 2001; 104: 2095-2100
33. Nattel S, Maguy A, Le Bouter S, Yeh Y-H. Arrhythmogenic ion channel remodeling in the heart: heart failure, myocardial infarctation, and atrial fibrillation. Physiol Rev 2007; 87: 425-456
34. Choy AM, Lang CC, Chomsky DM, et al. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation 1997; 96: 2149-2154
35. Marx SO, Kurokawa J, Reiken S, et al. Requirement of a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. Science 2002; 295: 496-499
36. Nattel S, Quantz MA. Pharmacological response of quinidine induced early afterdepolarization in canine cardiac Purkinje fibres: insights into underlying ionic mechanisms. Cardiovasc Res 1988; 22: 808-817
37. Roden DM. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 1998; 21: 1029-1034
38. Viswanathan PC, Rudy Y. Pause induced early afterdepolarizations in the long QT syndrome: a simulation study. Cardiovasc Res 1999; 42: 530-542
39. Vermeulen JT, McGuire MA, Opthof T, et al. Triggered activity and automaticity in ventricular trabeculae of failing human and rabbit hearts. Cardiovasc Res 1994; 28: 1547-1554
40. Pogwizd SM, Schlotthauer K, Li L, et al. Arrhythmogenesis and contractile dysfunction in heart failure: roles of sodium calcium exchange, inward rectifier potassium current, residual beta adrenergic responsiveness. Circ Res 2001; 88:1159-1167
41. Pogwizd SM, Bers DM. Cellular basis of triggered arrhythmias in heart failure. Trends Cardiovasc Med 2004; 14: 61-66
42. Ai X, Curran JW, Shannon TR, et al. Ca2+/calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca2+ leak in heart failure. Circ Res 2005; 97: 1314-1322
43. Rosenbaum MB, Blanco HH, Elizari MV, et al. Electronic modulation of the T wave and cardiac memory. Am J Cardiol 1982; 50: 213-222
44. Satoh T, Zipes DP. Rapid rates during bradycardia prolong ventricular refractoriness and facilitate ventricular tachycardia induction with cesium in dogs. Circulation 1996; 94: 217-227
45. Shivilkin A, Danilo P, Wang J, et al. Evolution and resolution of long term cardiac memory. Circulation 1998; 97: 1810-1817
46. Yu HG, McKinnon D, Dixon JE, et al. Transient outward current, Ito1, is altered in cardiac memory. Circulation 1999; 99: 1898-1905
47. Libbus I, Wan X, Rosenbaum DS. Electrotonic load triggers remodeling of repolarizing current Ito in ventricle. Am J Physiol Heart Circ Physiol 2004; H1901-9.
48. Lin JC, Quasny H.A. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine. Pharmacotherapy 1997; 17: 626-630
49. Damkier P, Hansen LL, Brosen K. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol 1999; 48: 829-838
50. Gennari FJ. Hypokalemia. N Engl J Med 1998; 337: 451-458
51. Turgeon J, Daleau P, Bennett PB, et al. Block of Iks, the slow component of the delayed rectifier K1 current, by the diuretic agent indapamide in guinea pig myocytes. Circ Res 1994; 75: 879-886
52. Fiset C, Drolet B, Hamelin BA, Turgeon J. Block of Iks by the diuretic agent indapamide modulates cardiac electrophysiological effects of the class III antiarrhythmic drug dl-sotalol. J Pharmacol Exp Ther 1997; 283: 148-156
53. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003; 89: 1363-1372
54. Shantsila E, Watson T, Lip GYH. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias. Europace 2007; 9 (suppl 4): iv37-44.
55. Chiang C. Drug-induced long QT syndrome. J Med Biol Eng 2006; 26: 107-113
56. Pérez Riera AP, Uchida AH, Ferreira C, et al. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome. Circ J 2008; 15: 209-219
57. Lacy CF, Armstrong LL, Goldman MP, Lance L.L. Drug Information Handbook, 17th ed. Hudson, Ohio: Lexi Comp 2008.
58. Maisel WH, Kuntz KM, Reimold SC, et al. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med 1997; 127: 281-284
59. Paul AA, Witchel HJ, Hancox J.C. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide. Biochem Biophys Res Commun 2001; 280: 1243-1250
60. Ellenbogen KA, Wood MA, Stambler BS. Procainamide: a perspective on its value and danger. Heart Dis Stroke 1993; 2: 473-476
61. Foo D, Ng KS. Electrocardiographical case. A case of wide complex tachycardia. Singapore Med J 2005; 46: 245-248
62. Grace AA, Camm AJ. Quinidine. N Engl J Med 1998; 338: 35-45.
63. Yang F, Hanon S, Lam P, Schweitzer P. Quinidine revisited. Am J Med 2009; 122: 317-321
64. Follmer CH, Colatsky TJ. Block of delayed rectifier potassium current, IK, by flecainide and E-4031 in cat ventricular myocytes. Circulation 1990; 82: 289-293
65. Priori SG, Napolitano C, Schwartz PJ, et al. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation 2000; 102: 945-947
66. Benito B, Brugada R, Perich RM, et al. A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation. Heart Rhythm 2008; 5: 1434-1440
67. Beinart R, Michailidis A, Gurevitz OT, Glikson M. Is flecainide dangerous in long QT-3 patients? Pacing Clin Electrophysiol 2009; 32: 143-145
68. Letsas KP, Efremidis M, Kounas SP, et al. Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors. Clin Res Cardiol 2009; 98: 208-212
69. Jafari-Fesharaki M, Scheinman MM. Adverse effects of amiodarone. Pacing Clin Electrophysiol 1998; 21: 108-120
70. Kochiadakis GE, Igoumenidis NE, Solomou MC, et al. Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion. Cardiovasc Drugs Ther 1998; 12: 75-81.
71. Kochiadakis GE, Igoumenidis NE, Parthenakis FI, et al. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol 1999; 33: 966-971
72. Vardas PE, Kochiadakis GE, Igoumenidis NE, et al. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: A randomized, controlled study [in Process Citation]. Chest 2000; 117: 1538-1545
73. Sung RJ, Tan HL, Karagounis L, et al. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebocontrolled study. Sotalol Multicenter Study Group. Am Heart J 1995; 129: 739-748
74. Vos MA, Golitsyn SR, Stangl K, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart 1998; 79: 568-575
75. Reisinger J, Gatterer E, Heinze G, et al. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998; 81: 1450-1454
76. Chung MK, Schweikert RA, Wilkoff BL, et al. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol 1998; 32: 169-176
77. Kiehn J, Lacerda AE, Wible B, Brown A.M. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. Circulation 1996; 94: 2572-2579
78. Pedersen HS, Elming H, Seibaek M, et al. DIAMOND Study Group. Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. Am J Cardiol 2007; 100: 876-880
79. Aström-Lilja C, Odeberg JM, Ekman E, Hägg S. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf 2008; 17: 587-592
80. Srivastava A, Khan MA, Watkiss J. Post induction arrhythmia in a renal patient: an unexpected risk factor. Anaesthesia 2009; 64: 439-443
81. Yalta K, Turgut O, Yilmaz A, et al. Torsades de pointes with a severely prolonged QT interval induced by an initial low dose sotalol intake. Int J Cardiol 2007; 116: e95-7.
82. Letsas KP, Efremidis M, Sideris M. Sotalol unmasks susceptibility to drug-induced long QT syndrome and torsades de pointes. Int J Cardiol 2008; 124: 366-367
83. Cherpanath TG, Geisler FE, van der Meer BJ, van Veer NE, Alings A.M. Suicide attempt with sotalol: a proarrhythmic intoxication. Ned Tijdschr Geneeskd 2007; 151: 2214-2218
84. Linz DK, Afkham F, Itter G, Rütten H, Wirth KJ. Effect of atrial electrical remodeling on the efficacy of antiarrhythmic drugs: comparison of amiodarone with I(Kr)- and I(to)/IKur-blockade in vivo. J Cardiovasc Electrophysiol 2007; 18: 1313-1320
85. Ravina T, Ravina P, Gutierrez J. Acquired long QT syndrome: Unequal regression of Amiodarone induced repolarization lengthening. Int J Cardiol 2008; 124: 395-399
86. Imai S, Saito F, Takase H, et al. Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm. Circ J 2008; 72: 709-715
87. Fujiki A, Tsuneda T, Sugao M, Mizumaki K, Inoue H. Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. Am J Cardiol 2003; 92: 472-475
88. Nakazato Y, Yasuda M, Sasaki A, et al. Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. Circ J 2005; 69: 44-48
89. Miyaji K, Tada H, Fukushima KK, et al. Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs. Circ J 2007; 71: 1250-1257
90. Prystowsky EN. Effects of bepridil on cardiac electrophysiologic properties. Am J Cardiol 1992; 69: 63D-7D.
91. Yasuda M, Nakazato Y, Sasaki A, et al. Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. Circ J 2006; 70: 662-666
92. Wang CP, Guo GB. Indapamide induced syncope in a patient with long QT syndrome. Pacing Clin Electrophysiol 2002; 25: 1397-1399
93. Lu Y, Yue L, Wang Z, Nattel S. Effects of the diuretic agent indapamide on Na+, transient outward, and delayed rectifier currents in canine atrial myocytes. Circ Res 1998; 83: 158-166
94. Letsas KP, Alexanian IP, Pappas LK, et al. Letter to the editor. QT interval prolongation and torsade de pointes associated with indapamide. Int J Cardiol 2006; 112: 373-374
95. Kijtawornrat A, Hamlin RL, Hamlin DM. Effects of ambasilide in isolated perfused guinea pig heart: use dependence. Cardiovasc Toxicol 2005; 5: 53-62. (Pubitemid 40655443)
96. Sager PT, Nademanee K, Antimisiaris M, et al. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans. Circulation 1993; 88: 1072-1082
97. Wong W, Pavlou HN, Birgersdotter UM, et al. Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmias. Am J Cardiol 1992; 69: 206-212
98. SoRelle R. Withdrawal of Posicor from market [news]. Circulation 1998; 98: 831-832
99. Levine TB, Bernink PJ, Caspi A, et al. Effect of mibefradil, a Ttype calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial. Circulation 2000; 101: 758-764
100. Miyajima K, Minatoguchi S, Ito Y, et al. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension. Hypertens Res 2007; 30: 307-313
101. Abraham J, Mudd JO, Kapur N, Klein K, Champion HC, Wittstein IS. Stress cardiomyopathy after intravenous administration of catecholamines and beta-receptor agonists. J Am Coll Cardiol 2009; 53: 1320-1325
102. Quan F, Peng G, Kangan C, Dayi H, Cuilan L, Richard CC. Dobutamine Infusion for Unmasking Long QT Syndrome and Torsades de Pointes. Clin Cardiol 2009; 32(6): E78-E81.
103. Peitz GJ, Malesker MA, Sojka SG. Aliskiren-induced QT interval prolongation. South Med J 2009; 102: 411-412
104. Vincent GM, Schwartz PJ, Denjoy I, et al. High efficacy of betablockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of betablocker treatment "failures". Circulation 2009; 119: 215-221
105. Erdil F, Demirbilek S, Begec Z, et al. The effect of esmolol on the QTc interval during induction of anaesthesia in patients with coronary artery disease. Anaesthesia 2009; 64: 246-250